Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg in healthy male volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: HanAll BioPharma Co., Ltd.
• Treatments: Amlodipine; Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

1. Healthy male, Age 20 to 45

2. Subject must be willing and able to provide written informed consent to the study.

Exclusion Criteria:

1. History of any significant sickness, liver system, gall bladder system, kidney, nerve system, respiratory system, blood tumor, endocrine system, urinary system, mental disease, muscloskeletal system, immunity system, the ear, nose and throat system and cardiovascular system.

2. History of any significant gastrointestinal system and surgery of gastrointestinal.

3. History of any significant hypersensitivity to amlodipine, candesartan, aspirin, antibiotic.

4. Over 10 tobaccos a day.

5. Other condition which in the opinion of the investigator preclude endrollment into the study.